A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)
Clinical trial NCT06995430 · COMPLETED
Trial details
- NCT number
- NCT06995430
- Sponsor
- GlaxoSmithKline
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-07
- Primary completion
- 2025-12-08
- Enrollment
- 312
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.